This article is more than 5 years old. Information may no longer be current.
Travoprost/timolol fixed combo trial results promising
Click Here to Manage Email Alerts
FORT WORTH, Texas — A fixed combination of travoprost and timolol showed similar results to concomitant therapy with the two glaucoma agents separately, according to early trial results released by the drug’s maker.
Alcon noted in a press release it has filed a New Drug Application with the Food and Drug Administration for a combination of Travatan (travoprost 0.004%) and timolol 0.5% in a once-daily medication for the treatment of glaucoma.
According to the news release, Travatan/Timolol Fixed Combination (TTFC) lowered IOP by as much as 12 mm Hg. The change in IOP produced by TTFC was 2 mm Hg more than that produced by travoprost 0.004% alone at the 8 a.m. time point. At the 10 a.m. and 4 p.m. time points, TTFC reduced IOP between 1 mm Hg and 2 mm Hg more than travoprost 0.004% alone.
Two other phase 3 trials compared the IOP-lowering effect of TTFC to concomitant therapy consisting of travoprost 0.004% in the evening and timolol 0.5% in the morning. The effect of TTFC was not statistically different from concomitant therapy at the 8 a.m. time point or at most other measured time points, the press release noted.
According to Alcon, a fixed-combination drug that combines a prostaglandin with a beta-blocker (such as TTFC) is not currently available in the U.S.